Recent FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) was based on data from LOTIS-2ZYNLONTA™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCLLAUSANNE, Switzerland (BUSINES.
ADC Therapeutics SA: ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology
ZYNLONTA demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCL
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of LOTIS-2, a multicenter, open-label, single-arm Phase 2 clinical trial evaluating the safety and efficacy of single-agent ZYNLONTA in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following two or more systemic treatments, have been published online in
Telemedicine is a tool not a replacement for your doctor’s touch
Earlier in the pandemic it was vital to see doctors over platforms like Zoom or FaceTime when in-person appointments posed risks of coronavirus exposure. Insurers were forced often for the first time to reimburse for all sorts of virtual medical visits and generally at the same price as in-person consultations.
By April 2020, one national study found, telemedicine visits already accounted for 13% of all medical claims compared with 0.15% a year earlier. And covid hadn t seriously hit much of the country yet. By May, Johns Hopkins neurology department was conducting 95% of patient visits virtually compared with just 10 such visits weekly the year before, for example.
Telemedicine Is a Tool — Not a Replacement for a Doctor s Touch medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.